Leadgene Biomedical, a company dedicated to the development and manufacturing of innovative in vitro diagnostic (IVD) reagents, has announced that its proprietary “Leadgene Indoxyl Sulfate (IS) ELISA Kit” has received marketing authorization from Singapore’s Health Sciences Authority (HSA). This diagnostic tool allows for rapid measurement of the protein-bound uremic toxin indoxyl sulfate, supporting clinicians in evaluating kidney function. The approval marks a key milestone in Leadgene’s expansion into Southeast Asia and underscores the company’s technological capabilities and product quality. The kit is expected to play a vital role in the early diagnosis and precision management of chronic kidney disease (CKD) worldwide.
Indoxyl sulfate (IS) is a protein-bound uremic toxin produced by the metabolism of dietary tryptophan by gut microbiota. In healthy individuals, IS is efficiently excreted by the kidneys. However, when renal function is impaired—particularly with reduced glomerular filtration rate (GFR)—IS accumulates in the body. Studies have shown that elevated IS levels exert direct nephrotoxic effects by increasing oxidative stress, inducing tubular damage and fibrosis, and accelerating CKD progression toward end-stage renal disease (ESRD). Alarmingly, high IS levels are closely associated with increased overall mortality, cardiovascular disease, renal osteodystrophy, sarcopenia, and neurodegenerative disorders. Therefore, regular monitoring of IS is clinically valuable for detecting early kidney function decline and assessing the risk of CKD progression and complications.
“We’re not just offering a testing tool—we aim to empower physicians and patients with the ability to anticipate and respond early,” said Leadgene Biomedical Chairman Yung-Chun Chuang. He emphasized that precise detection of IS levels helps clinicians identify early-stage kidney deterioration, equipping patients with timely treatment options and enabling the development of personalized care strategies to delay disease progression. The core technology of this product is a global first and has secured multiple international patents. It previously received marketing approval from Taiwan’s Food and Drug Administration (TFDA), CE-IVD certification in the EU, and approval in Vietnam. The product was also awarded the 2024 Symbol of National Quality (SNQ) mark in Taiwan, attesting to its quality.
Beyond regulatory success, the “Leadgene Indoxyl Sulfate ELISA Kit” has been widely recognized by the academic and clinical communities for its outstanding performance. It is already in use at several leading institutions, including Taipei Medical University Hospital, National Cheng Kung University Hospital, Yonghe Cardinal Tien Hospital, St. Martin De Porres Hospital, and Taiwan E&Q Clinical Laboratory. To date, over six international scientific papers have utilized the kit in studies on protein-bound uremic toxins, further validating its reliability and consistency in research applications.
Resource: 腎病「精準檢測」利器！ 再獲國際IVD認證 偉喬生醫硫酸吲哚酚檢測試劑組 獲新加坡上市許可
